Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Hemophilia A Market 2015-2019

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 68 | Code: MRS - 35079


Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.

The analysts forecast global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.

Covered in this report

This report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.

The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Baxter International
  • Bayer's
  • CSL Behring
  • Novo Nordisk
  • Pfizer

Other prominent vendors

  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios
  • Biogen Idec
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Dong-A Socio
  • Emergent BioSolutions
  • Grifols
  • Inspiration Biopharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • OPKO Health
  • rEVO Biologics
  • Sangamo BioSciences
  • Spark Therapeutics
  • UniQure

Market driver

  • Development of drugs with prolonged action
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Advances in technology
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors


Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Diagnosis
Treatment
Epidemiology

PART 06: Pipeline portfolio
Key information on pipeline candidates

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Segmentation by type of therapy
Plasma-derived therapies
Recombinant therapies

PART 09: Segmentation by disease management
On-demand therapy
Prophylaxis
Inhibitors

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Baxter
Bayer HealthCare
CSL Behring
Pfizer

PART 18: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Number of prevalence cases of hemophilia A in five countries 2011
Exhibit 03: Key late-stage drugs under development for hemophilia A
Exhibit 04: Global hemophilia A drugs market 2014-2019 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Global hemophilia A drugs market by type of therapy
Exhibit 07: Segmentation by type of therapy for hemophilia A
Exhibit 08: Global hemophilia A drugs market by disease management
Exhibit 09: Types of prophylaxis
Exhibit 10: Segmentation by disease management of hemophilia A
Exhibit 11: Segmentation of global hemophilia A drugs market by geography in 2014
Exhibit 12: Impact of drivers
Exhibit 13: Impact of drivers and challenges
Exhibit 14: Baxter: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
Exhibit 15: Baxter: Key takeaways
Exhibit 16: Novo Nordisk: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
Exhibit 17: Novo Nordisk: Key takeaways
Exhibit 18: Bayer: Global YoY growth and revenue of Kogenate FS 2012-2014 ($ millions)
Exhibit 19: Bayer's: Key takeaways
Exhibit 20: Pfizer: Global YoY growth and revenue of Xyntha/ReFactoAF 2012-2014 ($ millions)
Exhibit 21: Pfizer: Key takeaways
Exhibit 22: CSL Behring: Global YoY growth and revenue of hemophilia products 2013-2014 ($ millions)
Exhibit 23: CSL Behring: Key takeaways
Exhibit 24: CSL Behring: Product segmentation by revenue 2014
Exhibit 25: CSL Behring: Geographical segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 27: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 28: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 29: Novo Nordisk: R&D expenditure 2014

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2500 View Pricing